Digestive comfort

Digestive comfort

Benegut® is a patented botanical extract from shiso leaves (Perilla frutescens) combining antispasmodic effect and action on tight junction leakage to reduce the root causes of functional dyspepsia. Benegut® is clinically proven to contribute to a significant reduction of intestinal discomfort. Supported with an acute and a chronic clinical trial. 300 mg/day.

Benegut® - Key features

  • Contributes to the reinforcement of tight junctions of cells

  • Provides an antispasmodic effect

  • Clinically proven to rapidly reduce overall gastrointestinal discomfort

  • Improves bloating, feeling of fullness and abdominal comfort

Science supporting Benegut®

Benegut® is targeting digestive comfort and functional dyspepsia symptoms. Its mechanism of action on exploring antispasmodic effects and preventive effects on tight junction leakage, some of the causes of functional dyspepsia, have been studied in-vivo and in-vitro. The clinical benefits of Benegut® have been demonstrated in a chronic and an acute gold-standard clinical studies.


Benegut® is a patented botanical extract obtained by water extraction of shiso leaves (Perilla frutescens L.), an annual edible herbaceous plant harvested on the island of Hokkaido in Japan. Benegut® is standardised on a special flavonoid fraction and its key active ingredient Vicenin 2 and on rosmarinic acid, determined by HPLC.

Bioactive compounds
    Rosmarinic acid                  ≥ 0.05%
    Special flavonoids fraction   ≥ 0.18%
                     incl. Vicenin-2   ≥ 0.007%

Composition: Shiso leaf extract (Perilla Frutescens L.)

Recommended daily dosage: 300 mg

Mechanism of action

Benegut® contributes to the reinforcement of tight junctions of cells.

The effect of Benegut® on TNFα-caused tight junction leakage was investigated on intestinal epithelial cells (Caco-2).

Benegut® showed a significant restorative effect on the tight junctions, after 6 hours until 24h against TNF-α treatment.

Benegut® shows anti-spasmodic effects.

Benegut® and isolated Vicenin-2 significantly decreased acetylcholine- or Ba2+ -induced rat ileum contractions, indicating an antispasmodic effect.


Clinically supported benefits

Benegut® helps to significantly improve GI symptoms over time.

Double-blind, randomised, placebo-controlled study.


Esslingen, Germany
BioTeSys GmbH

4 weeks

50 subjects
41 women & 9 men
Age: 30-70 years old
BMI: 19-30 kg/m2
Healthy subjects with gastrointestinal discomfort evaluated by a questionnaire


Baseline  –  Run-in Phase (2 weeks)
Supplementation – Intervention phase (4 weeks) divided in: Visit 1 (0-15 days) & Visit 2 (15-30 days)

Gastrointestinal symptoms: Bloating/distension, passage of gas, GI rumbling, feeling of fullness, abdominal discomfort
on a Likert scale from 0 to 4

Confounding factors monitored: Perceived stress PSQ20 score; stool frequency  


2 x 150 mg/day


After 4 weeks, all criteria for digestive comfort have been significantly improved following the consumption of Benegut®:

  • Lowered bloating
  • Reduced passage of gas
  • Reduced gastrointestinal rumbling
  • Improved feeling of fullness
  • Reduced overall abdominal discomfort

Benegut® improves digestive comfort after the first intake.

Acute, double-blind, randomised, powered cross-over study.

LOCATIONS Esslingen, Germany
BioTeSys GmbH
Acute - Over 90min

30 subjects
Age: 18-30 years old
BMI: 19-30 kg/m2
Healthy subjects


Gastrointestinal symptoms after a high caloric meal
on a VAS scale of 0 to 10 & Likert scale


300 mg of Benegut or placebo taken immediately after meal

Benegut® consumption helped to significantly reduce overall gastrointestinal discomfort 90 mins after the consumption of a high caloric meal.

Feeling of fullness, bloating and burping are the three main symptoms driving the improvement in gastrointestinal discomfort.


Benegut® is safe.

No adverse event linked to Benegut® supplementation has been recorded.

Regulatory & Certifications

Non-GMO, Halal, Kosher, gluten-free, suitable for vegetarians


2023 Publication pending
Buchwald-Werner S. et al. BMC Complement Altern Med. 2014; 14:173

Verspohl J. et al. Phytomedicine. 2013; 427–431
Buchwald-Werner S. et al. Agro Food Industry Hi Tech. 2016; vol. 27(5)

WO2013079623. Vicenin 2 and derivatives thereof for use as antispasmodic and/or prokinetic agent.

This website is intended to provide information about Fytexia’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public.  Statements used on this website have not been evaluated by the Food and Drug Administration or any other competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.